NervGen Pharma Corp. is conducting the Phase 3 RESTORE trial for NVG-291, a drug aimed at improving function in chronic spinal cord injury patients. The trial is designed to detect a specific treatment effect without interim analysis, making the final results decisive. Funding is secured through the topline readout expected in the first half of 2028, but investors should be aware of potential dilution risks due to increased shares and an unused $50 million ATM facility. The stock is rated a Buy with a risk-adjusted value estimate of $4.50 to $6.50 per share, though upside is limited by trial binary risk and dilution concerns.
NervGen Pharma's Phase 3 trial news is presented with a snapshot of the health sector on Pluang. For readers following health stocks, 13 of 100 US health-sector stocks rose while 86 fell. Notable movers include BIO at USD 356.57 with a -5.60% change, TMDX at USD 79.00 with a -5.33% change and 100% buy order activity, and AXGN at USD 39.85 with a -4.94% change. This data is as of Oct 02, 2026 03:12 WIB.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
